Characterization of the DNA binding properties of ridinilazole, a phase III antibiotic for treatment of Clostridioides difficile Infection
You are leaving Smmttx.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible
for
its contents.
Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.
To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.
Characterization of the DNA binding properties of ridinilazole, a phase III antibiotic for treatment of Clostridioides difficile Infection